Myeloproliferative and lymphoproliferative disorders: State of the art

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) like PV, ET, and PMF are clonal disorders with risks of vascular events and transformation.
• Secondary malignancies, particularly lymphoproliferative disorders (LPNs), occur more frequently in MPN patients than the general population.
• Recent discussions explore a potential link between JAK inhibitor treatment in MPNs and LPN development.

Purpose of the Study:

• To review the role of JAK2 and the JAK/STAT pathway in MPN and LPN.
• To investigate the influence of genetic background and cytoreductive drugs on the co-occurrence of MPN and LPN.
• To discuss whether increased lymphoma risk with JAK inhibitors is specific to ruxolitinib or a broader JAK1/2 inhibition phenomenon.

Main Methods:

• Literature review focusing on the JAK/STAT pathway, genetic factors, and cytoreductive therapies in MPN and LPN.
• Analysis of existing studies on JAK inhibitor treatment and secondary malignancy risk in MPN patients.
• Discussion of the specificity of JAK1 versus JAK2 targeting in relation to LPN development.

Main Results:

• The JAK/STAT pathway is implicated in both MPN and LPN pathogenesis.
• Genetic predisposition and cytoreductive drug use may influence the development of both MPN and LPN.
• Evidence suggests a potential association between JAK inhibitor use and increased LPN risk, though specificity requires further investigation.

Conclusions:

• The coexistence of MPN and LPN warrants further investigation, particularly concerning the role of JAK signaling.
• Understanding the interplay of genetic factors, therapies, and the JAK/STAT pathway is crucial for managing MPN patients at risk of LPN.
• Further research is needed to elucidate the precise mechanisms linking JAK inhibition to LPN development and to guide therapeutic strategies.